Page last updated: 2024-10-30

metformin and Atypical Mycobacterial Infection, Disseminated

metformin has been researched along with Atypical Mycobacterial Infection, Disseminated in 1 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Kim, HH1
Kim, S1
Kim, MA1
Jung, CH1
Chong, YP1
Shim, TS1
Kim, YJ1
Jo, KW1

Other Studies

1 other study available for metformin and Atypical Mycobacterial Infection, Disseminated

ArticleYear
Stratification of Nontuberculous Mycobacterial Disease Risk in Type 2 Diabetes Based on Metformin Use: a Population-Based Cohort Study in South Korea.
    Antimicrobial agents and chemotherapy, 2023, 06-15, Volume: 67, Issue:6

    Topics: Cohort Studies; Diabetes Mellitus, Type 2; Humans; Incidence; Lung Diseases; Metformin; Mycobacteriu

2023